Price$49.13+2.08 (+4.42%)
01:30 PM07:45 PM
News · 26 weeks86+343%
2025-12-282026-06-21
Mix4490d
- SEC Filings15(34%)
- Insider15(34%)
- Other7(16%)
- Analyst3(7%)
- Earnings2(5%)
- Offering2(5%)
Latest news
25 items- PRuniQure Announces Pricing of Upsized $225 Million Public OfferingLEXINGTON, Mass. and AMSTERDAM, June 23, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced the pricing of its previously announced underwritten public offering of 4,945,055 ordinary shares at a public offering price of $45.50 per share. The aggregate gross proceeds to uniQure from the offering, before deducting the underwriting discounts and commissions and offering expenses payable by uniQure, are expected to be approximately $225 million. All securities to be sold in the offering are being sold by uniQure. In addition, uniQure has granted to the underwriters a 30-d
- PRuniQure Announces $150 Million Proposed Public OfferingLEXINGTON, Mass. and AMSTERDAM, June 22, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that it has commenced a $150 million underwritten public offering of its ordinary shares and, in lieu of ordinary shares to certain investors, pre-funded warrants to purchase its ordinary shares. All securities to be sold in the offering will be offered by uniQure. In addition, uniQure intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of its ordinary shares on the same terms and conditions. The offering is subject to market and othe
- SECSEC Form 424B5 filed by uniQure N.V.424B5 - uniQure N.V. (0001590560) (Filer)
- INSIDERCEO, Managing Director Kapusta Matthew C exercised 67,237 units of Ordinary Shares at a strike of $20.24 and sold $9,371,612 worth of Ordinary Shares (206,100 units at $45.47) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 521,795 units (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERDirector Balachandran Madhavan exercised 11,685 units of Ordinary Shares at a strike of $24.97 and sold $526,485 worth of Ordinary Shares (11,685 units at $45.06) as part of a pre-agreed trading plan (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERDirector Kaye Jack exercised 5,295 units of Ordinary Shares at a strike of $31.71 and sold $225,408 worth of Ordinary Shares (5,295 units at $42.57) as part of a pre-agreed trading plan (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- SECuniQure N.V. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - uniQure N.V. (0001590560) (Filer)
- PRuniQure Announces Preliminary Data on the First Cohort in the Phase I/IIa Clinical Trial of AMT-260 in Refractory Mesial Temporal Lobe Epilepsy~ AMT-260 was generally well-tolerated with no serious adverse events observed to date, with early biological signals of potential therapeutic activity ~ LEXINGTON, Mass. and AMSTERDAM, June 19, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced initial six-month follow-up data on the first, low dose cohort of six patients in its ongoing Phase I/IIa trial of an investigational gene therapy candidate, AMT-260, for the treatment of refractory mesial temporal lobe epilepsy (MTLE). The data will be presented today, Friday, June 19, 2026, at the Epilepsy Foundation Pipeli
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- ANALYSTuniQure upgraded by Barclays with a new price targetBarclays upgraded uniQure from Equal Weight to Overweight and set a new price target of $65.00
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- INSIDERDirector Balachandran Madhavan exercised 10,000 units of Ordinary Shares at a strike of $8.49 and sold $278,500 worth of Ordinary Shares (10,000 units at $27.85) as part of a pre-agreed trading plan (SEC Form 4)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Legal Officer Potts Jeannette sold $144,908 worth of Ordinary Shares (5,237 units at $27.67), decreasing direct ownership by 4% to 133,246 units (SEC Form 4) to satisfy tax liability4 - uniQure N.V. (0001590560) (Issuer)
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- SECSEC Form 144 filed by uniQure N.V.144 - uniQure N.V. (0001590560) (Subject)
- ANALYSTuniQure upgraded by Cantor Fitzgerald with a new price targetCantor Fitzgerald upgraded uniQure from Neutral to Overweight and set a new price target of $61.00
- ANALYSTuniQure upgraded by Cantor FitzgeraldCantor Fitzgerald upgraded uniQure from Neutral to Overweight
- PRBiotech's New Frontier: Companies Breaking Through Medicine's Toughest BarriersDENVER, June 17, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) – The biotechnology space is delivering a steady stream of potentially market-moving developments this week as companies across oncology, neuroscience, gene therapy, medical devices, and synthetic biology delivered significant regulatory, clinical, and commercial updates. NeOnc Technologies Holdings Advances Toward Critical Neuro-Oncology Milestones NeOnc (NASDAQ:NTHI) is becoming one of the more closely watched emerging neuro-oncology companies after securing a significant international regulatory milestone. The Department of Health – Abu Dhabi granted Investigational New Drug (IND) authorization for NEO212, the company's ora
- SECuniQure N.V. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits8-K - uniQure N.V. (0001590560) (Filer)
- PRuniQure Announces Plan for BLA Submission for AMT-130 in Huntington's Disease~ 3-year analysis from the Phase I/II study can serve as the primary basis of a Biologics License Application for accelerated approval with FDA ~ ~ Company intends to submit the BLA in third quarter of 2026 ~ LEXINGTON, Mass. and AMSTERDAM, June 17, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ:QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that, during a recent Type B meeting with the U.S. Food and Drug Administration (FDA), the FDA communicated that the 3-year analysis from the Phase I/II study would be acceptable as the primary basis of a Biologics License Application (BLA) for the accelerated approval o
- SECuniQure N.V. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits8-K - uniQure N.V. (0001590560) (Filer)
- INSIDERDirector Meek David D. was granted 7,550 units of Ordinary Shares and sold $53,931 worth of Ordinary Shares (1,993 units at $27.06), increasing direct ownership by 16% to 39,747 units (SEC Form 4) (for withholding tax)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERDirector Gut Robert exercised 2,645 units of Ordinary Shares at a strike of $16.04, sold $270,486 worth of Ordinary Shares (10,278 units at $26.32) as part of a pre-agreed trading plan and was granted 7,550 units of Ordinary Shares, decreasing direct ownership by 0.26% to 32,259 units (SEC Form 4) (withholding tax)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERChief Customer & Strat Officer O'Keefe Kylie sold $431,228 worth of Ordinary Shares (15,936 units at $27.06), decreasing direct ownership by 13% to 108,864 units (SEC Form 4) (for tax liability)4 - uniQure N.V. (0001590560) (Issuer)
- INSIDERDirector Springhorn Jeremy P. was granted 7,550 units of Ordinary Shares and sold $53,931 worth of Ordinary Shares (1,993 units at $27.06), increasing direct ownership by 15% to 43,251 units (SEC Form 4) to satisfy withholding tax4 - uniQure N.V. (0001590560) (Issuer)
QURE FAQ
7 questionsWhat does uniQure N.V. do?
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. Its lead program is Etranacogene dezaparvovec (AMT-061), which is in Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also engages in developing AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease; AMT-060, which is in Phase I/II clinical trial for the treatment of hemophilia B; AMT-180 for the treatment of hemophilia A; AMT-190, an IV-administered adeno-associated...Where does QURE stock trade?
uniQure N.V. (QURE) is listed on NASDAQ.What sector and industry is QURE in?
uniQure N.V. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did uniQure N.V. go public?
uniQure N.V. (QURE) completed its IPO in 2014.What are analysts saying about QURE?
uniQure N.V. has had 8 recent analyst actions on file. The most recent action was from Barclays: Overweight on 2026-06-18. Recent price targets range from $1200.00 to $3500.00.What companies are similar to QURE?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), AZN (AstraZeneca PLC), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare QURE side-by-side with any of them on Quantisnow.How can I track QURE on Quantisnow?
Quantisnow aggregates uniQure N.V.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow QURE to receive live email and push alerts on every new disclosure.